What are the recommended dosing regimens for metoprolol for its various indications (e.g., hypertension, chronic stable angina, post‑myocardial infarction, heart failure with reduced ejection fraction, and intravenous use)?

Metoprolol Dosing Recommendations

For heart failure with reduced ejection fraction (HFrEF), start metoprolol succinate (CR/XL) at 12.5-25 mg once daily and titrate to a target dose of 200 mg once daily; for chronic stable angina or post-MI, use metoprolol tartrate 50-200 mg twice daily; and for acute MI, administer 5 mg IV every 5 minutes for 3 doses (total 15 mg), followed by 25-50 mg orally every 6 hours starting 15 minutes after the last IV dose.

Heart Failure with Reduced Ejection Fraction (HFrEF)

Use only metoprolol succinate (CR/XL) - this formulation has proven mortality benefit 1, 2.

Dosing Protocol:

• Starting dose: 12.5-25 mg once daily 1, 3
• Target dose: 200 mg once daily 1, 4
• Titration schedule: Double the dose at minimum 2-week intervals 1
• Goal: Achieve target dose or highest tolerated dose 1

Key Points:

• Metoprolol succinate 200 mg daily is the evidence-based target from MERIT-HF trial 2
• Some beta-blocker is better than no beta-blocker if target dose cannot be reached 1
• Only three beta-blockers reduce mortality in HF: bisoprolol, carvedilol, and metoprolol CR/XL - benefits are NOT a class effect 1
• Continue therapy indefinitely in patients with LVEF ≤40% 5, 6

Monitoring:

• Check heart rate, blood pressure, clinical status (especially signs of congestion), and body weight 1
• Monitor blood chemistry 1-2 weeks after initiation and after final dose titration 1

Acute Myocardial Infarction

Intravenous Administration (Early Treatment):

For hemodynamically stable patients without contraindications 7, 8, 9:

• Dose: 5 mg IV over 1-2 minutes
• Repeat: Every 5 minutes for total of 3 doses (15 mg total) 7, 8, 9
• Monitoring: Continuous blood pressure, heart rate, and ECG during IV administration 7, 9

Oral Transition:

• If full IV dose tolerated: Start 25-50 mg orally every 6 hours, beginning 15 minutes after last IV dose 7, 8, 7
• Continue: 48 hours at this dose 7
• Maintenance: Increase to 100 mg twice daily thereafter 7

Important Cautions:

Avoid IV beta-blockers in patients with 10, 7, 3:

• Signs of heart failure or hemodynamic instability
• Systolic BP <90 mmHg
• Heart rate <50 bpm or >110 bpm
• Evidence of low output state
• Killip Class II-III (increased shock risk)

The COMMIT trial demonstrated that early aggressive IV beta-blockade increases cardiogenic shock risk in hemodynamically compromised patients 7. For unstable patients, initiate oral therapy only after stabilization 10, 7.

Post-MI Continuation:

• Continue for at least 3 years in patients with normal LVEF 5
• Continue indefinitely in patients with LVEF ≤40% 5, 6

Recent evidence note: Contemporary meta-analyses suggest beta-blockers may not reduce mortality in post-MI patients with preserved LVEF (≥50%) in the modern reperfusion era 11, 12, 13, though they may benefit those with mildly reduced LVEF (40-49%) 11, 13.

Chronic Stable Angina and Hypertension

Metoprolol tartrate dosing 7, 10, 8:

• Starting dose: 50 mg twice daily
• Target range: 50-200 mg twice daily
• Titration: Adjust based on heart rate and blood pressure response

Alternative Once-Daily Dosing:

For hypertension, metoprolol can be given once daily at 100-200 mg 14, though twice-daily dosing is more commonly recommended for angina 7, 10, 15.

Unstable Angina/NSTEMI

Oral beta-blockers should be initiated within the first 24 hours in stable patients without contraindications 7, 10, 7.

Dosing Options:

• Metoprolol tartrate: 25-50 mg every 6 hours initially, then twice daily 10, 7
• Target heart rate: 50-60 bpm 7

Reserve IV administration for specific indications: ongoing rest pain with tachycardia or hypertension in hemodynamically stable patients 7, 10, 7.

Special Populations

Hepatic Impairment:

• Start at low doses with cautious gradual titration 9
• Metoprolol levels increase substantially with liver disease 9

Renal Impairment:

• No dose adjustment required 9

Elderly Patients:

• Use low initial starting doses 9
• More frequent monitoring due to decreased organ function 9

Reactive Airway Disease:

• Use cardioselective agent at reduced dose (e.g., 12.5 mg metoprolol orally) rather than complete avoidance 10, 8
• Consider short-acting formulation (metoprolol tartrate) initially for safety 10, 8

Critical Contraindications

Do not use beta-blockers acutely in 10, 8, 3:

• Marked first-degree AV block (PR >0.24 seconds)
• Second- or third-degree AV block without pacemaker
• Active asthma
• Severe LV dysfunction with signs of HF (rales, S3 gallop)
• Systolic BP <90 mmHg
• Heart rate <50 bpm
• Cardiogenic shock or high shock risk

Practical Pitfalls

1. Formulation matters: Metoprolol tartrate and succinate are NOT interchangeable - use succinate (CR/XL) for HFrEF 1, 2
2. Dose matters: The target dose for HF (200 mg daily) is higher than typical hypertension doses (25-100 mg daily) 4
3. Don't undertitrate: Medium doses do not provide the same mortality benefit as target doses 4
4. Temporary worsening is common: 20-30% of HF patients experience initial symptom deterioration - adjust diuretics rather than stopping beta-blocker 1
5. IV caution in acute MI: The benefit of IV administration is questionable and carries shock risk - oral initiation is safer for most stable patients 7, 10, 7